• SWORD Studies

    Josep M Llibre, Chien-Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre-Marie Girard, Lesley P Kahl, Elizabeth A Blair, Kostas Angelis, Brian Wynne, Kati Vandermeulen, Mark Underwood, Kim Smith, Martin Gartland, Michael Aboud January 5, 2018 Read More
  • FLAMINGO study (96-week data)

    Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

    Molina J-M, Clotet B, van Lunzen J, et al, on behalf of the FLAMINGO Study Team Lancet HIV 2015; 2: e127–36. Read More
  • VIKING-3 study (24-week data)

    Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Castagna A, Maggiolo F, Penco G, et al, for the VIKING-3 Study Group. J Infect Dis 2014; 210: 354–362. Read More
  • SPRING-2 study (96-week data)

    Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

    Raffi F, Jaeger H, Quiros-Roldan E, et al, on behalf of the extended SPRING-2 Study Group Lancet Infect Dis 2013; 13: 927–935. Read More
  • SAILING study (48-week data)

    Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

    Cahn P, Pozniak AL, Mingrone H, et al, on behalf of the extended SAILING Study Team Lancet 2013; 382: 700–708. Read More
  • SINGLE study (144-week data)

    Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naïve Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial

    Sharon Walmsley, MD, Axel Baumgarten, MD, Juan Berenguer, MD, Franco Felizarta, MD, Eric Florence, MD, Marie-Aude Khuong-Josses, MD, J. Michael Kilby, MD, Thomas Lutz, MD, Daniel Podzamczer, MD, Joaquin Portilla, MD, Norman Roth, MD, Deborah Wong, MSc, Catherine Granier, DESS, Brian Wynne, MD and Keith Pappa, PharmD J Acquir Immune Defic Syndr 2015;70:515-519 Read More

HIV Guidelines

Recommended guideline options for the treatment of HIV

UK/DTGP/0037/16(10) | November 2018